> Roche ($RHHBY) won the FDA's coveted "breakthrough" designation for a new use for its anti-inflammatory drug Actemra, in patients with systemic sclerosis. Release
> Novartis ($NVS) touted one-year data from its MEASURE 2 study showing that 74% of ankylosing spondylitis patients saw significant, sustained improvement with Cosentyx therapy. Release
> The National Institute for Health and Care Excellence turned down Celgene's ($CELG) psoriasis med Otezla, in contrast to the Scottish Medicines Consortium's decision in favor of the drug. Report
> Life sciences sales specialist Aktana rolled out a new product connecting its decision-making support solution to Veeva Systems' new CRM software. Release (PDF)
And Finally... Johnson & Johnson's ($JNJ) Tylenol brand ID'd Canada's most sleepless cities in a survey to help sell its sleep aids. Report